Comparison of Adherence and CD4 counts of HIV patients on various ART Regimens

Adiga S¹, Adiga U², Malawadi BN³

¹Dr Sachidananda Adiga, Associate Professor, Department of Pharmacology, ²Dr Usha Adiga, Associate Professor, Department of Biochemistry, ³Dr Malawadi BN, Assistant Professor, Department of Biochemistry, all are affiliated with Karwar Institute of Medical Sciences, Karwar. Karnataka, India.

Address for Correspondence: Dr. Sachidananda Adiga, Associate Professor, Department of Pharmacology, Karwar Institute of Medical Sciences, Karwar. Karnataka, India. E-mail : adigaiscool@yahoo.com

Abstract

Introduction: Inspite of HAART, it has been found that viral replication persists even when viral load is undetectable. Adherence has been reported to be positively associated with CD4 count in various settings. Objectives of our study were comparison of basal CD4 count of HIV patients on various ART regimens with that at six months and one year as well as finding correlation between percentage adherence to ART and CD4 counts at six months and one year. We also aimed to compare percentage adherence and CD4 counts of patients on various ART regimens. Methodology: A retrospective observational study was conducted on 63 HIV patients, receiving four antiretroviral regimens (AZT/3TC/NVP, AZT/3TC/EFV, d4T/3TC/NVP and d4T/3TC/EFV). Patient demography, drug regimen, baseline CD4 counts, serial CD4 counts (every six months), and adherence to ART (monthly) were recorded. Comparison of basal CD4 counts with that at six months and one year was done. Comparison of CD4 count and adherence were done between the groups. Results: An extremely significant elevation was seen in CD4 counts at six months and at one year (p < 0.0001). Linear regression showed a significant positive correlation (p = 0.037) between adherence and CD4 counts at one year. There was no significant difference in percentage adherence and CD4 counts between four groups. Conclusion: We conclude that optimal CD4 levels were obtained in patients on all four different regimens. However percentage adherence was suboptimal in all groups which caution to take appropriate measures to achieve optimal drug adherence.

Key words: Adherence, Antiretroviral therapy, CD4 Count, HIV Infection

Introduction

The treatment of HIV infection and AIDS is complex because of many reasons. The complexity of ART regimens used, duration of treatment, adherence to treatment, drug toxicities and opportunistic infections associated are the main contributing factors. Several studies have shown that nearly 25% of all patients discontinue their initial HAART regimen because of treatment failure, toxic effects or noncompliance within the first eight months of therapy [1, 2]. Many studies have shown that adherence to treatment is most important factor in deciding the progression of the disease and there are many factors associated with this [3-7]. The Indian national AIDS control organization guidelines recommended the use of two nucleoside reverse transcriptase inhibitors (NRTI) in combination with a non-nucleoside reverse transcriptase (NNRTI) in India. Zidovudine and lamivudine in combination with either nevirapine or efavirenz and stavudine, lamivudine in combination with nevirapine or efavirenz are commonly used regimens.

Primary objectives

1. Comparison of basal CD4 count of HIV patients on various ART regimens with that at six months and one year.
2. Correlate percentage adherence to ART and CD4 counts at six months and one year.

Secondary objective- Comparison of CD4 counts and percentage adherence to ART, among patients receiving different ART regimens.
Patients and Methods

A retrospective observational study on 63 adult HIV patients, receiving various antiretroviral regimens was conducted in a teaching hospital attached to Karwar Institute of Medical Sciences, Karwar Karnataka, India. Institutional ethics committee approval was sought. Data of patients who were diagnosed to be HIV positive, receiving HAART and were attending the hospital for regular follow up monthly was collected. Patients were evaluated during their scheduled follow up visits in detail, by measuring CD4 counts, hemogram and other laboratory parameters serially once in six months. Adherence to the regimen was assessed monthly.

Inclusion Criteria: Patients receiving one of the above mentioned regimens at least for one year.

Exclusion: Data of patients with less than one year of treatment, deaths within 1 year were excluded.

Data Collection- Data was extracted from Patient’s medical records using data collection form. Patient demography such as age, gender, medication prescribed (drug regimen), baseline CD4 cell counts, serially monitored CD4 count values (once in six months), adherence to ART by pill count method (monthly) were recorded.

Patients’ data was categorized into four groups based on the type of regimen.

Group 1: zidovudine, lamivudine, nevirapine (ZLN) AZT/3TC/NVP
Group 2: zidovudine, lamivudine, efavirenz (ZLE) AZT/3TC/EFV
Group 3: stavudine, lamivudine, nevirapine (SLN) d4T/3TC/NVP
Group 4: stavudine, lamivudine, efavirenz (SLE) d4T / 3TC / EFV

Standard drug dosages of the nucleoside reverse transcriptase inhibitors (NRTIs) were, zidovudine (AZT) 300 mg twice daily, lamivudine (3TC) 150 mg twice daily or 300 mg once daily, stavudine (d4T) 60 mg daily. Dosages of non-nucleoside reverse transcriptase inhibitors (NNRTIs) were nevirapine (NVP) 200 mg once daily for a 2-week lead-in period and then as 200 mg twice daily and efavirenz (EFV) 600 mg once daily. Demographic profile of patients are given in Table 1.

Table-1: Demographic profile of patients on different regimens.

<table>
<thead>
<tr>
<th></th>
<th>Group 1(ZLN)</th>
<th>Group 2(ZLE)</th>
<th>Group 3(SLN)</th>
<th>Group 4(SLE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>15</td>
<td>18</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td>Gender: Males</td>
<td>53.33%</td>
<td>50%</td>
<td>35.71%</td>
<td>68.75%</td>
</tr>
<tr>
<td></td>
<td>46.67%</td>
<td>50%</td>
<td>64.29%</td>
<td>31.25%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>35.67±2.38</td>
<td>39.39±1.89</td>
<td>31.92±4.2</td>
<td>39.38±2.54</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>51.13±3.06</td>
<td>46.42±1.95</td>
<td>35.29±3.65</td>
<td>46.69±3.09</td>
</tr>
</tbody>
</table>

Basal CD4 count and improvement in CD4 counts in subsequent follow up visits and adherence to ART are the tool to compare and measure the effectiveness of the regimens. CD4 count was measured by flow cytometric method. Percentage drug adherence was calculated by pill count method, which is a process oriented indicator. Adherence assessment was done monthly and mean was taken at six months and one year.

Statistical analysis was done by Graphpad Prism-7 statistical software. Student’s paired ‘t’ test was done to compare basal CD4 counts with that at six months and one year separately. Linear regression analysis was carried out to find the correlation between adherences and follow up CD4 counts, taking CD4 count as dependent variable. One way ANOVA test was used for the comparison of basal as well as CD4 counts at six months and one year, between as well as within the groups. Statistical significance was fixed at level 0.05.

Results

An extremely significant (p= 0.0000) elevation was seen in CD4 counts at 6 months as well as at 1 year (p < 0.0001) as shown in Table 2. When CD4 counts of 6 months were compared with that at 1 year, a less significant elevation (0.0273) was obtained. Linear regression showed a significant positive correlation (p = 0.037) between adherence and CD4 counts at 1 year (R=0.13, R²=0.02).
Table-2: Comparison of CD4 counts and percentage adherence in HIV patients.

<table>
<thead>
<tr>
<th></th>
<th>Before starting (A) ART(N=63) Mean ±SEM</th>
<th>At 6 months (B) (N=63) Mean ±SEM</th>
<th>At 1 year (C) (N=63) Mean ±SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD4 count</td>
<td>230.91 ± 26.79(A)</td>
<td>391.65 ± 34.03(B)</td>
<td>458.86±42.38(C)</td>
</tr>
<tr>
<td>Median</td>
<td>164</td>
<td>360</td>
<td>373</td>
</tr>
<tr>
<td>% of Adherence</td>
<td>---------</td>
<td>93.28±1.36</td>
<td>92.91±3.5</td>
</tr>
</tbody>
</table>

A Vs B : p = 0.0000, extremely significant
A Vs C : p < 0.0001, highly significant
B Vs C : p = 0.0273, significant

We did not find any significant difference in the CD4 counts (basal, six months and one year) between the four treatment regimens. However, a highly significant (p= 0.0021) elevation was seen in CD4 counts in group 1. A comparatively less significant elevation was seen in group 2 (p = 0.0461). No significant improvement was seen in group 3. A highly significant elevation was also seen in group 4 (p =0.006). Comparison of CD4 counts between the groups is given in Table 3.

Table-3: Comparison of percentage adherence and CD4 counts between different groups.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (ZLN) (N=15)</th>
<th>Group 2 (ZLE) (N=18)</th>
<th>Group 3 (SLN) (N=14)</th>
<th>Group 4 (SLE) (N=116)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal CD4 count</td>
<td>225.8 ± 28.9</td>
<td>196.22 ± 41.53</td>
<td>363.21±89.89</td>
<td>158.94±34.17</td>
</tr>
<tr>
<td>CD4 count at 6 months</td>
<td>406.53±62.11</td>
<td>357±73.43</td>
<td>482.57±86.22</td>
<td>337.13 ±46.72</td>
</tr>
<tr>
<td>CD4 count at 1 year</td>
<td>568.66±86.98</td>
<td>397.51±70.49</td>
<td>517.2±122.26</td>
<td>373.75±57.3</td>
</tr>
<tr>
<td>P value comparing all 3 CD4 counts</td>
<td>0.0021**</td>
<td>0.0461*</td>
<td>0.54</td>
<td>0.006**</td>
</tr>
<tr>
<td>Percentage of adherence at 6 months</td>
<td>93.71± 1.8</td>
<td>95.52±0.32</td>
<td>94.52±0.8</td>
<td>94.25±1.06</td>
</tr>
<tr>
<td>Percentage adherence at 1 year</td>
<td>95.21±1.35</td>
<td>95.86±0.5</td>
<td>95.19±0.74</td>
<td>94.38±0.6</td>
</tr>
</tbody>
</table>

*significant
**highly significant

There was no significant difference in percentage of adherence between the groups as well as within individual groups at six months and one year. No significant gender difference was observed in percentage adherence in our study.

Discussion

It is obvious from our findings that, CD4 counts were elevated during their initial one year treatment period. Extent of elevation was higher in the first six months as compared to the next six months. Positive correlation between percentage adherence and CD4 counts at one year suggests that, better the drug adherence, higher is the CD4 count. Our study is supported by a study by Ghate et al which suggests a significant elevation in CD4 counts if adherence is high [8]. Similar results were expressed in a South African study [9]. A study by Paterson and colleagues suggest that below 95%, adherence rate independently determines viral load [10].

WHO bulletin suggests that, response to ART therapy is said to be optimal if rise in median CD4 count is more than 50 cells/µl at six months and more than 100 cells/µl at one year [11]. As per these guidelines, our patients have shown optimal response to ART therapy. A few studies agree with our report in this regard [12,13].

Various Indian studies have reported that adherence rate ranges from 41%-97.3% [14-19] Compared to majority of these studies, adherence rate in our study is better. Even though we could achieve optimal CD4 counts,
percentage adherence is not more than 95% in all the groups. The national ART program in India considers adherence to be optimal if percentage adherence is more than or equal to 95%. This calls for a need to improve drug adherence in our patients. This not only improves immunological response and viral suppression, but also reduces drug resistant pathogens [20].

We did not find any significant difference in CD4 counts at six months and one year, among the four groups. A report by Joly et al supports our result [21]. This study suggests that regimens containing zidovudine exhibited same levels of antiviral activities as that containing stavudine. Based on this particular point of our result, we cannot decide which regimen is better. Values of percentage adherence to the regimens also are not helpful as they did not differ significantly between the groups.

However P values obtained by comparing basal, six months and one year CD4 counts within individual groups (Table 3) supports the extent of elevation in CD4 count. 2.5 times elevation of CD4 count was observed in patients receiving ZLN regimen (group 1) at the end of one year. Extent of CD4 count elevation was 2.35 times in patients on SLE (group 4).

Minimum elevation in CD4 count (1.4 times) was in patients receiving ZLE (group 2) whereas those on SLN (group 3) had least extent of elevation. Based on these findings, we can suggest that ZLN is the preferred drug in resource limited settings.

Missing scheduled follow up appointments and drug toxicities are responsible for suboptimal drug adherence [15, 22]. It is not just national ART program, but also patients and their family, health care providers and community have an important role in achieving optimal adherence rate.

Limitations of our study—Small sample size and method used for assessment of adherence are the limitations of our study. It has been suggested that pill count method is not the best standard for assessment of adherence as it does not match with self-reporting by patients.

More than one method has been recommended to achieve more accurate assessment of adherence [23]. However adherence assessment in our study was better than several studies which have obtained one time adherence [14, 15, 16, 17].

Conclusion

We conclude that optimal CD4 levels were obtained in patients on all four different regimens. However percentage adherence was suboptimal in all groups which cautions measures to be taken to achieve optimal drug adherence.

Acknowledgements—We thank Dr Anand Pawaskar, Medical Officer, ART center, Karwar for the support.

Funding: Nil, Conflict of interest: None initiated.

Permission from IRB: Yes

References


How to cite this article?